ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), announced the presentation of data from a study demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12 in a glioblastoma (brain cancer) murine model. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled, local expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares after opening at $3.80 moved to $4.00 on last trade day and at the end of the day closed at $3.60. Company price to sales ratio in past twelve months was calculated as 452.52 and price to cash ratio as 5.31. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) showed a negative weekly performance of -12.62%.
ISIS Pharmaceuticals (NASDAQ:ISIS) CEO Stanley Crooke sold 8,800 shares of the company’s stock in a transaction dated Wednesday, April 2nd. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) shares fell -5.78% in last trading session and ended the day on $33.90. ISIS return on equity ratio is recorded as -18.10% and its return on assets is -8.10%. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) yearly performance is 76.65%.
Zacks, current mean recommendation for Avanir Pharmaceuticals, Inc (NASDAQ:AVNR) is in the “buy range”. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) shares moved down -9.37% in last trading session and was closed at $3.29 while trading in range of $3.28 – $3.69 – Avanir Pharmaceuticals Inc (NASDAQ:AVNR) year to date (YTD) performance is -2.08%.
Shares of Dyax Corp (NASDAQ:DYAX) were up slightly to close the trading session on April 4 following the U.S. Food and Drug Administration’s (FDA) decision to approve the company’s subcutaneous treatment KALBITOR (ecallantide) for a wider patient population the day before. Dyax Corp. (NASDAQ:DYAX) weekly performance is -17.25%. On last trading day company shares ended up $7.15. Dyax Corp. (NASDAQ:DYAX) distance from 50-day simple moving average (SMA50) is -22.28%. Analysts mean target price for the company is $13.36.